{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:33:43Z","timestamp":1793655223605,"version":"4.5.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.phrs.2023.106774","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:45:00Z","timestamp":1681731900000},"page":"106774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"special_numbering":"C","title":["Rule of five violations among the FDA-approved small molecule protein kinase inhibitors"],"prefix":"10.1016","volume":"191","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.106774_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tips.2022.12.007","article-title":"Futibatinib (Lytgobi) for cholangiocarcinoma","volume":"44","author":"Roskoski","year":"2023","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2023.106774_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib6","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharm. Sci."},{"issue":"pii","key":"10.1016\/j.phrs.2023.106774_bib8","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.106774_bib9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.106774_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2023.106774_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib16","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2023.106774_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Disco Today"},{"key":"10.1016\/j.phrs.2023.106774_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11095-015-1779-y","article-title":"Thermodynamic proxies to compensate for biases in drug discovery methods","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2023.106774_bib26","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2023.106774_bib28","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \"drug-like\" properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib29","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib30","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1021\/acs.jmedchem.8b00077","article-title":"Lipophilic efficiency as an important metric in drug design","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib31","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/jm500515d","article-title":"Physicochemical descriptors of aromatic character and their use in drug discovery","volume":"57","author":"Ritchie","year":"2014","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib32","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2016.07.007","article-title":"Quality guidelines for oral drug candidates: dose, solubility and lipophilicity","volume":"21","author":"Bayliss","year":"2016","journal-title":"Drug Disco Today"},{"key":"10.1016\/j.phrs.2023.106774_bib33","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2023.106774_bib34","first-page":"63","article-title":"Molecular complexity: a simplified formula adapted to individual atoms. J Chem Inf Compout","volume":"27","author":"Hendrickson","year":"1987","journal-title":"Sci"},{"key":"10.1016\/j.phrs.2023.106774_bib35","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1021\/acs.chemrestox.8b00044","article-title":"Impact of physicochemical properties on dose and hepatotoxicity of oral drugs","volume":"31","author":"Leeson","year":"2018","journal-title":"Chem. Res Toxicol."},{"key":"10.1016\/j.phrs.2023.106774_bib37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2023.106774_bib38","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.5b01286","article-title":"How beyond rule of 5 drugs and clinical candidates bind to their targets","volume":"59","author":"Doak","year":"2016","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd.2018.52","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2023.106774_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib42","unstructured":"Bechman K., Galloway G.B., Winthrop K.L. Small-molecule protein kinase inhibitors and the risk of fungal infections. Curr Fungal Infect Rep. 10.1007\/s12281\u2013019-00350-w."},{"key":"10.1016\/j.phrs.2023.106774_bib43","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2023.106774_bib44","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorganic","volume":"6","author":"Liu","year":"1998","journal-title":"Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib45","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/ijms22020566","article-title":"The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification","volume":"22","author":"Wells","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2023.106774_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105412","article-title":"Posttranslational modifications as therapeutic targets for intestinal disorders","volume":"165","author":"Choo","year":"2021","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib47","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib48","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","article-title":"Small-molecule kinase inhibitors for the treatment of nononcologic diseases","volume":"64","author":"Xie","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib50","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/s41467-021-23165-1","article-title":"IDG-DREAM drug-kinase binding prediction challenge consortium, Oprea TI, Schlessinger A, Drewry DH, Stolovitzky G, Wennerberg K, Guinney J, Aittokallio T. Crowdsourced mapping of unexplored target space of kinase inhibitors","volume":"12","author":"Cicho\u0144ska","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2023.106774_bib51","doi-asserted-by":"crossref","first-page":"13764","DOI":"10.1002\/anie.201914525","article-title":"New promise and opportunities for allosteric kinase inhibitors","volume":"59","author":"Lu","year":"2020","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.phrs.2023.106774_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2023.106774_bib53","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-91442-8_18","article-title":"Osimertinib","volume":"211","author":"Malapelle","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.phrs.2023.106774_bib54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/d41573-023-00017-9","article-title":"The non-small-cell lung cancer drug market","volume":"22","author":"Nawaz","year":"2023","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2023.106774_bib58","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-91442-8_17","article-title":"Alectinib","volume":"211","author":"Herden","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2023.106774_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918789364","article-title":"Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy","volume":"10","author":"Vaval\u00e0","year":"2018","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.phrs.2023.106774_bib60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2023.106774_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41570-022-00451-0","article-title":"Rules were made to be broken","author":"Hartung","year":"2023","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.phrs.2023.106774_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:47:21Z","timestamp":1760914041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":62,"alternative-id":["S1043661823001305"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106774","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rule of five violations among the FDA-approved small molecule protein kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106774"}}